Israel Englander’s Soleno Therapeutics SLNO Stock Holding History

Israel Englander’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-20,000	Closed	-$670K	–	6357
2026 Q1	$670K	Sell	20,000 -7,000	-26%	-$274K	﹤0.01%	4626
2025 Q4	$1.25M	Sell	27,000 -180,700	-87%	-$9.91M	﹤0.01%	4325
2025 Q3	$14M	Buy	+207,700	New	+$15.4M	0.01%	2043
2025 Q2	–	Sell	-341,800	Closed	-$24.4M	–	6293
2025 Q1	$24.4M	Buy	341,800 +336,800	+6,736%	+$16.4M	0.01%	1328
2024 Q4	$225K	Buy	+5,000	New	+$259K	﹤0.01%	5238
2024 Q3	–	Sell	-20,000	Closed	-$816K	–	6447
2024 Q2	$816K	Buy	+20,000	New	+$848K	﹤0.01%	4246

Israel Englander's SLNO Position: Q2 2026 in Review

Israel Englander sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 606,513 shares — an estimated $20.3M sold.

Israel Englander first reported a position in SLNO in Q1 2020 and held it in 17 quarters. The position peaked at $66.2M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Israel Englander reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Israel Englander sold 606,513 Soleno Therapeutics shares in Q2 2026, an estimated $20.3M.
Israel Englander first reported a position in Soleno Therapeutics in Q1 2020 and held it in 17 quarters.
Israel Englander's Soleno Therapeutics position peaked at $66.2M in Q3 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.